Back to News
Market Impact: 0.2
Rezolute Consensus Price Target Increased by 18.70% to $9.28
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
Rezolute's average one-year analyst price target was raised 18.7% to $9.28 per share from $7.82 on September 11, 2026, according to Fintel-compiled estimates. The upward revision signals improved analyst valuation expectations for the biotech company, though the article provides no operating or clinical catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
RZLT0.45
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
- This hyperscaler made Goldman Sachs’ list of top picks for October